Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine

Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02229357

Enrollment

Registered

2014-09-01

Start date

2014-06-30

Completion date

2014-09-30

Last updated

2015-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Avian Influenza

Keywords

H5N2 Vaccine

Brief summary

This study aim to compare immunogenicity of the inactivated H5 influenza vaccine single dose between subjects previously vaccinated with LAIV H5N2 and naïve subjects

Detailed description

It is a non-randomized, open label study to evaluate a licensed OrniFlu® inactivated vaccine (produced by Microgen Russia) which will be given to healthy adult volunteers who participated in a double blind placebo-controlled study Protocol No.: GPO AVIAN FLU Vaccine-V02-2 at Vaccine Trial Centre and Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University in February to May 2013. A total of 60 subjects, of whom 40 received two doses of LAIV H5N2 (prime-boost group), and 20 received placebo (control group) in the previous study will be asked to return to the clinic to receive a single dose of an inactivated H5 influenza vaccine. Total foloww up is 90 days.

Interventions

BIOLOGICALOrniFlu® inactivated vaccine

All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

* Participated in the Phase II study Protocol No.: GPO AVIAN FLU Vaccine-V02-2 * Healthy * Age 18-49 years old * Having Thai ID card or equivalent * Anti HIV - Negative * All hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not higher than 1.5 time of normal value without any clinical finding from history and physical examination) * Able to read and write and sign written informed consent.

Exclusion criteria

* Known history of egg allergy * Having had recently influenza infection confirmed as H5 * Receiving other vaccination against H5N1 * History of bronchial asthma * History of chronic lung diseases * History of chronic rhinitis * History of immunodeficiency state * History of immunosuppression\< 6 months prior to immunization * History of heavy smoking (more than 5 packs per day) * History of alcoholic (pure drink 200 ml per day) * Acute infectious and noninfectious diseases (within 2 weeks) * HIV positives * The volunteers who have been taking immunoglobulin products or have had a blood transfusion during past three months before the beginning of the experiment * Participation in other research study or stop participant less than 1 month * Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding * Poultry workers

Design outcomes

Primary

Measure	Time frame
Proportion of subjects exhibiting sero-responses in each of the assays (HAI, microneutralization) in the prime-boost and the control groups.	12 Months

Secondary

Measure	Time frame
Post-vaccination injection site and systemic reactogenicity and adverse events to the H5 inactivated influenza vaccine in subjects previously primed with LAIV H5N2 and in naïve subjects.	12 Month

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026